2024
Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer
Sundaresan V, Wang R, Long J, Sprenkle P, Seibert T, Loeb S, Cooperberg M, Catalona W, Ma X, Gross C, Leapman M. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urology Practice 2024, 11: 965-973. PMID: 39196719, DOI: 10.1097/upj.0000000000000679.Peer-Reviewed Original ResearchLocalized prostate cancerClinically localized prostate cancerHigh-risk diseaseProstate MRIProstate cancerTreatment intensificationIntensified treatmentGenomic testingTreated patientsProstate magnetic resonance imagingEnd Results databaseLong-term patient outcomesProstate cancer prognosisRetrospective cohort studyAssociated with decreased oddsRisk stratification toolPrimary study outcomeAssociated with increased oddsMagnetic resonance imagingResults databaseStratification toolTreatment patientsCohort studyRisk strataCancer prognosis
2023
Associations between patient sociodemographic factors and non-treatment for localized prostate cancer.
Novosel M, Smani S, Marks V, Jeong F, Sprenkle P, Leapman M. Associations between patient sociodemographic factors and non-treatment for localized prostate cancer. Journal Of Clinical Oncology 2023, 41: 307-307. DOI: 10.1200/jco.2023.41.6_suppl.307.Peer-Reviewed Original ResearchHigh-risk prostate cancerLocalized prostate cancerAggressive prostate cancerProstate cancerWhite patientsLower oddsDefinitive treatmentRisk strataSociodemographic factorsMean patient ageNational Cancer DatabaseHigh-risk diseasePatient sociodemographic factorsMultivariable logistic regressionClinical risk criteriaPatient ageImproved survivalBlack patientsInitial treatmentRisk diseaseAsian patientsRetrospective studyBlack raceInsurance statusPatient race